Doctors don't always know if the joint replacement they are implanting in you will succeed or fail due to a lack of a national registry tracking such instances.

Doctors don't always know if the joint replacement they are implanting in you will succeed or fail due to a lack of a national registry tracking such instances.

How informed are doctors?

How informed are doctors?

The answer is not obvious. Doctors know enormous amounts of data and have years of clinical experience. Many have solid science backgrounds and some conduct research keeping them at the top of their field. Most rely on published studies to make their decisions on which products to use.

However, only a small percentage of all published studies are Level 1 studies, the studies with data that is reliably true. Very few doctors actually conduct outcome studies on the techniques they use. Only a small number of doctors participate in wide clinical trials or device registries that track the outcomes of implants they use such as artificial joints, vessel stents, meshes for hernias, etc. In fact, there are no national registries of any orthopaedic surgical implant used in America. Shocking? That means that when a doctor implants a total knee or a hip prosthesis, there is no national registry tracking whether or not those implants fail. There isn't a state or local registry either. There isn't even a company registry. The only way most doctors know if a device fails is if the patient comes back to them. If the patient moves away or is angry about their outcome, the doctor may never know.

And it is not just implants. There is no registry or required postmarket approval (meaning after the FDA gives its initial blessing) for drugs or braces or breathing devices or just about anything doctors place into or on patients. We rely solely on reports to the doctor and then hopefully the doctor reporting to the FDA.

Now, it might be argued that the rigorous initial FDA approval process makes all products highly likely to be safe and effective. It's true that this process is arduous and expensive. So much so that few new products are actually being introduced, which is problematic. The process now is estimated to take an average of 4½ years for a new device to complete pilot and pivotal clinical phases with average costs of $30 million for low- to moderate-risk devices and a whopping $91 million for higher-risk devices. For new drugs, the costs are in the hundreds of millions of dollars.

So what is the solution? How can we get new and improved devices for our patients and find out whether they actually work? The answer lies in a nonintuitive combination of relaxing the rules for approving medical devices while strengthening the requirement to report any problems.

We could start with a new way of approving medical devices. It would go like this: A company completes all the safety testing required and then conducts a Phase I clinical trial in a small number of patients required to prove safety, not efficacy. The company is then allowed to release (sell) the product to the public with a strict Web-reporting program in place so that any complication, no matter how small, is reported by the patient and/or the doctor, and each report is public. By crowdsourcing the entire experience, experts from across the globe can comment on the efficacy of the device and problems can be immediately identified. With this system, companies are freed from the burden of decades of expensive studies to prove efficacy in a relatively small clinical trial, they can sell and create revenue immediately and, importantly, doctors and patients will actually know which devices work and which don't.

By gradually extending this to a comprehensive Web-based national medical products reporting program for devices and treatments currently on the market, we can then collect real time actual information on whether or not they work.

Well informed doctors could be at hand.

Dr. Kevin R. Stone is an orthopedic surgeon at The Stone Clinic and chairman of the Stone Research Foundation in San Francisco. He pioneers advanced orthopedic surgical and rehabilitation techniques to repair, regenerate and replace damaged cartilage and ligaments. For more info, visit www.stoneclinic.com.

FeaturesKevin R. Stone

Just Posted

Cabernet Sauvignon grapes sit in a container after being crushed at Smith-Madrone Winery in St. Helena, Calif. on Thursday, Sept. 9, 2021. (Courtesy Smith-Madrone Winery)
San Francisco’s ‘Champagne problems’ — Wine industry suffers supply chain woes

‘Everywhere you turn, things that were easy are no longer easy’

Glasses behind the bar at LUNA in the Mission District on Friday, Oct. 15, 2021. Glassware is just one of the many things restaurants have had trouble keeping in stock as supply chain problems ripple outward. (Kevin N. Hume/The Examiner)
SF restaurants face product shortages and skyrocketing costs

‘The supply chain crisis has impacted us in almost every way imaginable’

A Giants fans hangs his head in disbelief after the Dodgers won the NLDS in a controversial finish to a tight Game 5. (Chris Victorio/Special to The Examiner)
Giants dream season ends at the hands of the Dodgers, 2-1

A masterful game comes down to the bottom of the ninth, and San Francisco came up short

<strong>Workers with Urban Alchemy and the Downtown Streets Team clean at Seventh and Market streets on Oct. 12. <ins>(Kevin N. Hume/The Examiner)</ins> </strong>
<ins></ins>
Why is it so hard to keep San Francisco’s streets clean?

Some blame bureaucracy, others say it’s the residents’ fault

Speaker of the House Nancy Pelosi — seen in Washington, D.C., on Tuesday — touted Congressional Democrats’ infrastructure bill in San Francisco on Thursday. (Stefani Reynolds/The New York Times)
Pelosi touts infrastructure bill as it nears finish line

Climate change, social safety net among major priorities of Democrats’ 10-year funding measure

Most Read